Chromium Picolinate Supplement May Affect Depression

Chromium Picolinate Supplement May Affect Depression

PURCHASE, N.Y.--Nutrition 21 announced itschromium picolinate supplement, Zeramax, may be a feasible therapy fordepression, as demonstrated by a pilot study conducted at Duke UniversityMedical Center in Durham, N.C. Results of the study were presented at the AnnualMeeting of the American College of Neuropsychopharmacology on Dec. 10 in SanJuan, Puerto Rico, and were accepted for publication in the Journal ofBiological Psychiatry.

In line with the Duke University findings, Nutrition 21announced an agreement with Comprehensive NeuroScience Inc. (CNS), based inWhite Plains, N.Y., to conduct further research with Zeramax in the hopes ofconfirming the results from the Duke study.

"Given the remarkable promise of [the Duke] research, weidentified additional experts in the field of neuroscience and are honored tonow collaborate with CNS on the Zeramax Research Program," said GailMontgomery, president and chief executive officer of Nutrition 21 (www.nutrition21.com)."Nutrition 21's objective is to better understand chromium picolinate'sunderlying mechanisms of action in brain health and incorporate these findingsinto the development and responsible marketing of a clinically supportedproprietary supplement for promoting good mental health."